Volume 1.21 | Jun 11

Prostate Cell News 1.21, June 11, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Researchers Discover Melanoma Drug Target that Occurs in Prostate Cancer
Researchers have discovered the RAF oncogene that drives fatal melanomas may also drive the aggressive forms of prostate cancer in the clinic. [Press release from the University of Michigan Comprehensive Cancer Center discussing online prepublication in Nature Medicine]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies


Protein Could Heal Erectile Dysfunction After Cancer Surgery
After men have surgery to remove a cancerous prostate gland, up to 80 percent of them will lose the ability to have an erection because of damage to a critical nerve that runs along the prostate. New research shows the damaged nerve can be regenerated more quickly with the sonic hedgehog protein delivered via a nanofiber gel. [Press release from the Northwestern University Feinberg School of Medicine discussing research presented at the American Urological Association 2010 Annual Meeting]

Genetic Markers Could Predict Prostate Cancer in Younger Men, Study Finds
Prostate cancer has become more common in younger men, and it’s often more aggressive in these men. A new study has found that a series of genetic mutations could help detect this early onset prostate cancer. [Press release from the University of Michigan Comprehensive Cancer Center discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]

Delay in Surgery Not Likely to Worsen Tumors in Men with Low-Risk Prostate Cancer
Johns Hopkins experts have found that men enrolled in an active surveillance program for prostate cancer that eventually needed surgery to remove their prostates fared just as well as men who opted to remove the gland immediately, except if a follow-up biopsy during surveillance showed high-grade cancer. [Press release from EurekAlert! discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]

Blood Vessel-Blocking Drug Slows Prostate Cancer Progression: Experts
A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University. [The Medical News]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies


The Phosphoinositide 3-Kinase Regulatory Subunit p85(Alpha) Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling
Expression of Pik3r1, the gene encoding p85, is decreased in human prostate, lung, ovarian, bladder, and liver cancers, consistent with the possibility that p85 has tumor suppressor properties. Researchers tested this hypothesis by studying mice with a liver-specific deletion of the Pik3r1 gene. [Cancer Res]

PSA Reduces Prostate Cancer Cell Motility by Stimulating TRPM8 Activity and Plasma Membrane Expression
In this study, researchers identified the well-known prostate cancer marker, prostate-specific antigen (PSA), as a physiological transient receptor potential melastatin 8 (TRPM8) agonist. [Oncogene]

Inhibition of Prostate Cancer Growth and Metastasis Using Small Interference RNA Specific for Minichromosome Complex Maintenance Component 7
In this study, researchers constructed a vector that constitutively expresses small interference RNA (siRNA) specific for MCM7. [Gene Ther]

Micronutrients Attenuate Progression of Prostate Cancer by Elevating the Endogenous Inhibitor of Angiogenesis, Platelet Factor-4
Researchers present unprecedented data whereby these combined micronutrients effectively promotes tumor dormancy in early prostate cancer, following initiation mutations that may drive the angiogenesis-dependent response of the tumor, by inducing platelet factor-4 expression and concentrating it at the tumor endothelium through enhanced platelet binding. [BMC Cancer]


Surgery Confounds Biology: The Predictive Value of Stage, Grade and Prostate-Specific Antigen for Recurrence After Radical Prostatectomy as a Function of Surgeon Experience
Here researchers evaluate the association between several biological predictors and biochemical recurrence across varying surgical experience. [Int J Cancer]

Periostin is Up-Regulated in High Grade and High Stage Prostate Cancer
Here, researchers evaluated periostin expression in prostate cancer cells and peritumoural stroma immunohistochemically in two independent prostate cancer cohorts, including a training cohort (n=93) and a test cohort (n=325). [BMC Cancer]


Data Presented at ASCO Show Chronix Biomedical’s DNA Blood Tests Detect Breast and Prostate Cancer with 92% Sensitivity and 100% Specificity
Chronix Biomedical reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. [Chronix Biomedical Press Release]

30 Johns Hopkins Researchers Receive Maryland Stem Cell Funding
Thirty Johns Hopkins researchers have been awarded funding from the Maryland Stem Cell Research Commission under the Maryland Stem Cell Research Act of 2006. [Johns Hopkins Medicine Press Release]

Studies Suggest New Treatment Paradigms for Ovarian, Prostate Cancers
Both the ovarian and prostate cancer trials could change clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting radiation therapy for locally advanced prostate cancer, according to researchers. [Bloomberg Businessweek]


STAR METRICS: New Way to Measure the Impact of Federally Funded Research
A new initiative–Science and Technology for America’s Reinvestment: Measuring the Effect of Research on Innovation, Competitiveness and Science, or STAR METRICS–promises to monitor the impact of federal science investments on employment, knowledge generation, and health outcomes. [National Institutes of Health, United States]

FDA Announces Collaboration with Drugs.com
The U.S. Food and Drug Administration announced that it will collaborate with the website Drugs.com to expand access to the FDA’s consumer health information. [Food and Drug Administration, United States]

Administrative Supplements to Increase Public Awareness of Pediatric Cancers and Available Treatments and Research (NOT-CA-10-026)
[National Institutes of Health, United States]

2010 Biological License Application Approvals [Food and Drug Administration, United States]

2010 Biological Device Application Approvals [Food and Drug Administration, United States]


International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

CHI’s 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
August 17-19, 2010
Cambridge, United States

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us